The higher risk of serious bleeding caused by aspirin disappears after stopping the drug, indicating that the body’s ability to control bleeding returns to normal once aspirin is no longer taken.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of post-discontinuation bleeding outcomes across all aspirin RCTs would determine whether hemorrhage risk consistently returns to baseline after stopping aspirin in older adults.
A systematic review and meta-analysis pooling individual-level bleeding outcomes from all RCTs of aspirin for primary prevention in adults aged 65+, comparing major hemorrhage incidence during active use versus after discontinuation, with standardized definitions and adjustment for duration of prior use and baseline risk.
A new RCT could measure the time course of platelet function recovery and bleeding risk after aspirin cessation in older adults.
A double-blind RCT of 300 adults aged 70+ on daily aspirin, randomized to continue aspirin or switch to placebo at 5 years, with serial measurements of platelet aggregation, thromboxane B2, and bleeding time at baseline, 1 month, 3 months, and 6 months after discontinuation, and tracking of clinical bleeding events.
A cohort study could assess whether bleeding risk returns to baseline at different rates in older adults with varying baseline hemostatic profiles.
A prospective cohort of 5,000 older adults discontinuing aspirin after 3–7 years, with annual measurements of hemoglobin, platelet count, and von Willebrand factor, and tracking of bleeding events over 5 years, stratified by baseline anemia or GI history.
A case-control study could identify whether individuals who experience bleeding after aspirin cessation differ in residual drug levels or genetic variants affecting platelet recovery.
A nested case-control study comparing 400 older adults with major hemorrhage within 1 year of aspirin cessation to 1,200 matched controls, measuring serum salicylate levels and genotypes (e.g., COX-1 polymorphisms) at time of discontinuation and 3 months later.
A cross-sectional survey could estimate the proportion of older adults who report bleeding after stopping aspirin, but cannot establish causality or timing.
A national survey of 6,000 adults aged 70+ who discontinued aspirin, asking whether they experienced any major bleeding event within 1 year of stopping, with self-reported events confirmed by medical records.